UK Supreme Court issues Warner-Lambert v Actavis ruling
14-11-2018
Warner-Lambert v Actavis: a summary from the UK Supreme Court hearing
21-02-2018
Dmitrii_Guzhanin / iStockphoto.com
The UK Supreme Court’s decision in Warner-Lambert v Actavis is disappointing for pharmaceutical innovators, and enforcing second medical use patents may now be more challenging, lawyers have told LSIPR.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Warner-Lambert, Pfizer, Actavis, Mylan, UK Supreme Court, pregabalin, Lyrica, second medical use patent, plausibility, sufficiency, pain treatment, patent
